A Phase 1 interventional study of Autologous genetically modified MAGE-A4ᶜ¹º³²T cells and Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation in Urinary Bladder Cancer, Melanoma and Head and Neck Cancer, sponsored by USWM CT, LLC. Active, not recruiting at 11 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by USWM CT, LLC · Phase 1, Interventional, and Treatment
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors. This study has a substudy component that will investigate the safety and tolerability of MAGE-A4c1032T cell therapy in combination with low dose radiation in up to 10 subjects.
1,798 studies on the registry are indexed under Urinary Bladder Neoplasms; 445 are open to participants now.
This study's enrollment of 71 is above the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.
Browse Urinary Bladder Neoplasms studies →USWM CT, LLC is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
7. Subject has anticipated > 6 months prior to leukapheresis and >3 months prior to lymphodepletion.
Exclusion Criteria:
Additional Exclusion Criteria for the Radiation Substudy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Genetic: Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
Radiation: Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
Infusion of autologous genetically modified MAGE-A4ᶜ¹º³²T on Day 1
Up to 10 subjects will be considered for Radiation sub-study. Radiation with an intensity of 1.4Gy for 5 days before infusion of MAGE-A4c1032T cells
Adverse Events (AE) Including Serious Adverse Events (SAE)
An AE was defined as any untoward medical occurrence in a clinical study participant who received a pharmaceutical product, regardless of causality. An AE was , therefore, any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with AEs (including SAEs) are presented.
Time frame: From the start of lymphodepleting chemotherapy until end of interventional phase (up to 3.2 years).
Peak Persistence
Peak persistence of afamitresgene autoleucel cells was reported as vector copy numbers per microgram of genomic DNA from peripheral blood mononuclear cell (PBMC).
Time frame: From afamitresgene autoleucel infusion up to 18 months post-infusion
Replication Competent Lentivirus (RCL)
The presence of RCL was assessed by quantitative polymerase chain reaction (qPCR) targeting a segment of the vesicular stomatitis virus glycoprotein (VSV-G) coding sequence.
Time frame: From afamitresgene autoleucel infusion to 3 months post-infusion
Overall Response Rate (ORR)
ORR, defined as the proportion of participants with Best Overall Response (BOR) of confirmed completed response (CR) or partial response (PR) among participants with measurable disease at Baseline. The ORR was based on the assessment of response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by local radiologist. Participants with unknown or missing response were treated as non-responders.
Time frame: From afamitresgene autoleucel infusion until disease progression/recurrence (up to 3.2 years)
Best Overall Response (BOR)
BOR was defined as the best response recorded from the date of T-cell infusion until disease progression. Response categories from best to worst were, confirmed CR, confirmed PR, stable disease (SD), progressive disease (PD), and not evaluable (NE) (per RECIST v1.1)
Time frame: From afamitresgene autoleucel infusion until disease progression/recurrence (up to 3.2 years)
Time to Response (TTR)
TTR was defined as the interval between the date of the first T-cell infusion and the earliest date of the first documented confirmed CR or confirmed PR.
Time frame: From afamitresgene autoleucel infusion until first documented confirmed CR or PR
Duration of Response (DoR)
DoR was measured from the first CR/PR (whichever was first recorded) until the first date of progressive disease.
Time frame: From initial confirmed response (DR or PR) until PD or censored date. is defined as all participants who had not experienced the event of interest (i.e. ongoing, event free) at the time of the data cut off (used for the analysis).
Duration of Stable Disease (DoSD)
DoSD was defined as the time from the date of T-cell infusion to the first date of the radiological PD. This analysis of DoSD only applied to participants with BOR as confirmed CR, confirmed PR, or confirmed SD.
Time frame: From date of afamitresgene autoleucel infusion to first date of radiological PD or censored date
Progression Free Survival (PFS)
PFS was defined as the time from the date of the first T-cell infusion to the first date of the radiological PD or death date (due to any reason), whichever event was earlier.
Time frame: From afamitresgene autoleucel infusion until first documented PD or death due to any cause, whichever comes first, or censored date.
Overall Survival (OS)
OS was defined as the time from the date of afamitresgene autoleucel infusion to the date of death (due to any reason).
Time frame: From afamitresgene autoleucel infusion until death due to any reason or censored date From afamitresgene autoleucel infusion until death due to any reason or censored date
This was an open-label Phase 1 dose escalation study of afamitresgene autoleucel in HLA-A\*02 positive participants with MAGE-A4 expressing unresectable locally advanced or metastatic cancer of the following types: urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal (squamous and adenocarcinoma), gastric, synovial sarcoma, or MRCLS. This study had a substudy component that investigated the safety and tolerability of afamitresgene autoleucel in combination with low dose radiation.
| Milestone | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel, Group 3 + Expansion | Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel |
|---|---|---|---|---|
| Started | 3 | 3 | 32 | 4 |
| Received afamitresgene autoleucel | 3 | 3 | 32 | 4 |
| Completed | 3 | 3 | 29 | 4 |
| Not completed | 0 | 0 | 3 | 0 |
| Withdrew: Ongoing in interventional phase at data cut-off (1sep2020) | 0 | 0 | 3 | 0 |
An AE was defined as any untoward medical occurrence in a clinical study participant who received a pharmaceutical product, regardless of causality. An AE was , therefore, any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with AEs (including SAEs) are presented.
| Participants | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel, Group 3 + Expansion | Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel |
|---|---|---|---|---|
| Adverse Events (AE) Including Serious Adverse Events (SAE) | 3 | 3 | 32 | 4 |
Peak persistence of afamitresgene autoleucel cells was reported as vector copy numbers per microgram of genomic DNA from peripheral blood mononuclear cell (PBMC).
| DNA copies/microgram | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel Group 3 + Expansion | Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel |
|---|---|---|---|---|
| Peak Persistence | 10766.23 ± 12504.705 | 88900.26 ± 53873.432 | 165035.89 ± 99806.129 | 185,532.5800 ± 116322.7494 |
The presence of RCL was assessed by quantitative polymerase chain reaction (qPCR) targeting a segment of the vesicular stomatitis virus glycoprotein (VSV-G) coding sequence.
| Participants | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel, Group 3 + Expansion | Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel |
|---|---|---|---|---|
| Replication Competent Lentivirus (RCL) | 0 | 0 | 0 | 0 |
ORR, defined as the proportion of participants with Best Overall Response (BOR) of confirmed completed response (CR) or partial response (PR) among participants with measurable disease at Baseline. The ORR was based on the assessment of response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by local radiologist. Participants with unknown or missing response were treated as non-responders.
| Participants | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel, Group 3 + Expansion | Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel |
|---|---|---|---|---|
| Overall Response Rate (ORR) | 0 | 0 | 9 | 0 |
BOR was defined as the best response recorded from the date of T-cell infusion until disease progression. Response categories from best to worst were, confirmed CR, confirmed PR, stable disease (SD), progressive disease (PD), and not evaluable (NE) (per RECIST v1.1)
| Participants | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel, Group 3 + Expansion | Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel |
|---|---|---|---|---|
| Complete response | 0 | 0 | 0 | 0 |
| Partial response | 0 | 0 | 9 | 1 |
| Stable disease | 2 | 3 | 14 | 3 |
| Progressive disease (PD) | 1 | 0 | 6 | 0 |
| Not evaluable | 0 | 0 | 3 | 0 |
TTR was defined as the interval between the date of the first T-cell infusion and the earliest date of the first documented confirmed CR or confirmed PR.
| Weeks | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel, Group 3 + Expansion | Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel |
|---|---|---|---|---|
| Time to Response (TTR) | — | — | 6.4 (6.143 to 24.143) | NA (NA to NA) |
DoR was measured from the first CR/PR (whichever was first recorded) until the first date of progressive disease.
| Weeks | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel Group 3 + Expansion | Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel |
|---|---|---|---|---|
| Duration of Response (DoR) | — | — | 25.6 (12.286 to NA) | NA (NA to NA) |
DoSD was defined as the time from the date of T-cell infusion to the first date of the radiological PD. This analysis of DoSD only applied to participants with BOR as confirmed CR, confirmed PR, or confirmed SD.
| Weeks | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel, Group 3 + Expansion | Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel |
|---|---|---|---|---|
| Duration of Stable Disease (DoSD) | 12.3 (NA to NA) | 12.1 (NA to NA) | 20.4 (12.286 to 37.857) | 25.143 (13.143 to NA) |
PFS was defined as the time from the date of the first T-cell infusion to the first date of the radiological PD or death date (due to any reason), whichever event was earlier.
| Weeks | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel, Group 3 + Expansion | Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel |
|---|---|---|---|---|
| Progression Free Survival (PFS) | 8.9 (5.571 to 12.286) | 12.1 (10.857 to 12.143) | 12.4 (10.000 to 20.429) | 19.143 (11.571 to NA) |
OS was defined as the time from the date of afamitresgene autoleucel infusion to the date of death (due to any reason).
| Weeks | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel Group 3 + Expansion | Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel |
|---|---|---|---|---|
| Overall Survival (OS) | 19.8 (18.857 to 20.714) | NA (NA to NA) | 42.9 (25.429 to NA) | NA (11.571 to NA) |
Collected over From the start of lymphodepleting chemotherapy until end of interventional phase (up to 3.2 years post-Infusion).From the start of LDR until data cut off (up to 1.7 years post-radiation).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Afamitresgene Autoleucel, Group 1 | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Afamitresgene Autoleucel, Group 2 | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Afamitresgene Autoleucel, Group 3 + Expansion | 15/32 (46.9%) | 23/32 (71.9%) | 32/32 (100%) |
| Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel | 2/4 (50%) | 3/4 (75%) | 4/4 (100%) |
| Event | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel, Group 3 + Expansion | Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel |
|---|---|---|---|---|
| Cytokine release syndromeImmune system disorders | 1/3 | 0/3 | 8/32 | 0/4 |
| SepsisInfections and infestations | 0/3 | 1/3 | 1/32 | 0/4 |
| PancytopeniaBlood and lymphatic system disorders | 0/3 | 1/3 | 3/32 | 0/4 |
| Atrial fibrillationCardiac disorders | 1/3 | 0/3 | 1/32 | 0/4 |
| EncephalopathyNervous system disorders | 1/3 | 0/3 | 0/32 | 0/4 |
| SyncopeNervous system disorders | 1/3 | 0/3 | 0/32 | 0/4 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/3 | 1/3 | 1/32 | 0/4 |
| Small intestinal obstructionGastrointestinal disorders | 0/3 | 1/3 | 0/32 | 0/4 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/3 | 0/3 | 0/32 | 0/4 |
| HyponatraemiaMetabolism and nutrition disorders | 1/3 | 0/3 | 0/32 | 0/4 |
| Event | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel, Group 3 + Expansion | Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel |
|---|---|---|---|---|
| Lymphocyte count decreasedInvestigations | 3/3 | 3/3 | 31/32 | 4/4 |
| White blood cell count decreasedInvestigations | 3/3 | 3/3 | 28/32 | 4/4 |
| Neutrophil count decreasedInvestigations | 3/3 | 3/3 | 27/32 | 4/4 |
| NauseaGastrointestinal disorders | 3/3 | 2/3 | 19/32 | 2/4 |
| FatigueGeneral disorders | 3/3 | 2/3 | 19/32 | 2/4 |
| PyrexiaGeneral disorders | 1/3 | 3/3 | 18/32 | 3/4 |
| Decreased appetiteMetabolism and nutrition disorders | 3/3 | 2/3 | 11/32 | 1/4 |
| HeadacheNervous system disorders | 0/3 | 3/3 | 7/32 | 2/4 |
| AnaemiaBlood and lymphatic system disorders | 2/3 | 2/3 | 23/32 | 3/4 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/3 | 2/3 | 12/32 | 3/4 |
Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel
| Age, Categorical(Participants) | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel, Group 3 + Expansion | Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 3 | 24 | 3 | 31 |
| >=65 years | 2 | 0 | 8 | 1 | 11 |
| Sex: Female, Male(Participants) | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel, Group 3 + Expansion | Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel | Total |
|---|---|---|---|---|---|
| Female | 3 | 3 | 10 | 3 | 19 |
| Male | 0 | 0 | 22 | 1 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel, Group 3 + Expansion | Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 0 | 2 |
| Not Hispanic or Latino | 3 | 2 | 31 | 4 | 40 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Afamitresgene Autoleucel, Group 1 | Afamitresgene Autoleucel, Group 2 | Afamitresgene Autoleucel, Group 3 + Expansion | Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 1 |
| White | 3 | 3 | 29 | 3 | 38 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2017 to primary completion in Dec 2022, 67 months.
Results were first posted in May 2026, 3 years 4 months after primary completion.
Of 80 industry-sponsored phase 1 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 67 months is above that.
Counting every sponsor, half of 145 studies reached it within 43 months; a quarter within 29 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
USWM CT, LLC